Loading...
Loading...
Innovent Biologics Inc/ADR
Innovent Biologics Inc/ADR. Spoken Alpha tracks IVBXF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks IVBXF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IVBXF.
curl https://api.spokenalpha.com/v1/companies/IVBXF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.40 | $3.72 | +45.1% | -5.0% | -4.8% |
| Q4 FY2026 | $5.53 | $3.74 | +47.9% | -2.4% | -0.9% |
| Q3 FY2026 | $5.12 | $3.81 | +34.3% | -3.0% | -4.5% |
| Q2 FY2026 | $5.11 | $3.77 | +35.5% | +1.2% | 0.0% |
| Q1 FY2025 | $5.71 | $4.02 | +42.0% | -5.8% | -6.9% |
| Q4 FY2025 | $5.24 | $3.89 | +34.7% | -5.1% | -6.4% |
| Q3 FY2025 | $5.96 | $4.00 | +48.9% | -3.0% | -3.8% |
| Q2 FY2025 | $5.64 | $4.10 | +37.6% | -5.3% | -3.0% |
| Q1 FY2024 | $5.86 | $4.01 | +46.2% | +3.7% | +3.0% |
| Q4 FY2024 | $6.13 | $4.14 | +48.1% | -1.2% | -1.2% |